The total return over the past 12 months is +516.69% vs. +16.94% for the S&P 500. So far it's up +208.44% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +516.53% | +102.02% | +6.20% | (49.07%) | (40.35%) | N/A |
| Total Return CAGR | +516.69% | +102.05% | +6.20% | (49.07%) | (40.35%) | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
SELLAS Life Sciences Group, Inc. (SLS)
| Year | Start price | End price | SLS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.77 | $11.63 | +208.44% | +14.51% | +193.93% |
| 2025 | $1.04 | $3.77 | +262.42% | +17.72% | +244.70% |
| 2024 | $1.06 | $1.04 | (1.79%) | +24.89% | (26.68%) |
| 2023 | $2.36 | $1.06 | (55.08%) | +26.19% | (81.27%) |
| 2022 | $5.53 | $2.36 | (57.35%) | (18.17%) | (39.18%) |
| 2021 | $5.81 | $5.53 | (4.83%) | +28.74% | (33.57%) |
| 2020 | $4.30 | $5.81 | +35.12% | +18.37% | +16.75% |
| 2019 | $61.50 | $4.30 | (93.01%) | +31.22% | (124.23%) |
| 2018 | $390.00 | $61.50 | (84.23%) | (4.56%) | (79.67%) |
| 2017 | $2,910.00 | $390.00 | (86.60%) | +21.70% | (108.30%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
